Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016
Authors: Monzr M. Al Malki
Richard Jones
Qing Ma
Dean Lee
Yair Reisner
Jeffrey S. Miller
Peter Lang
Suradej Hongeng
Parameswaran Hari
Samuel Strober
Jianhua Yu
Richard Maziarz
Domenico Mavilio
Denis Claude Roy
Chiara Bonini
Richard E. Champlin
Ephraim J. Fuchs
Stefan O. Ciurea
Humanitas University
IRCCS San Raffaele Scientific Institute
Stanford University School of Medicine
Università degli Studi di Milano
University of Minnesota Twin Cities
Universitätsklinikum Tübingen Medizinische Fakultät
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Weizmann Institute of Science Israel
Oregon Health and Science University
University of Texas MD Anderson Cancer Center
Mahidol University
Medical College of Wisconsin
Hopital Maisonneuve-Rosemont
City of Hope National Med Center
Ohio State University
Children's Hospital Columbus
Keywords: Medicine
Issue Date: 1-May-2018
Citation: Biology of Blood and Marrow Transplantation. Vol.24, No.5 (2018), 895-908
Abstract: © 2018 The American Society for Blood and Marrow Transplantation The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34 + cell selection, “megadoses” of purified CD34 + cells, or selective depletion of T cells) or newer platforms of in vivo depletion of T cells, with either post-transplantation high-dose cyclophosphamide or intensified immune suppression, have contributed to better outcomes, with survival similar to that in HLA-matched donor transplantation. Further efforts are underway to control viral reactivation using modified T cells, improve immunologic reconstitution, and decrease the relapse rate post-transplantation using donor-derived cellular therapy products, such as genetically modified donor lymphocytes and natural killer cells. Improvements in treatment-related mortality have allowed the extension of haploidentical donor transplants to patients with hemoglobinopathies, such as thalassemia and sickle cell disease, and the possible development of platforms for immunotherapy in solid tumors. Moreover, combining HSCT from a related donor with solid organ transplantation could allow early tapering of immunosuppression in recipients of solid organ transplants and hopefully prevent organ rejection in this setting. This symposium summarizes some of the most important recent advances in HaploSCT and provides a glimpse in the future of fast growing field.
ISSN: 15236536
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.